Brand Identity
Genoskin supports CoViD19 research!
Genoskin COVID-19 research preferred access program On Friday, March 13th 2020, Genoskin launched a preferred access program for all research teams actively developing therapeutic and vaccine technologies for the COVID-19 pandemic. The World Health Organization (WHO) officially declared on March 11th, the outbreak of COVID-19 a pandemic. The disease caused by SARS-CoV-2 has spread globally. Over 130,000 individuals are affected so
US Patent for human skin models
Genoskin obtains US patent for skin models Genoskin is pleased to announce the approval of a US patent for our “system for the maintenance and survival of skin biopsies in transport and its applications”. The patent describes our method to transform human skin biopsies in ready-to-use and functional ex vivo skin models. The human skin biopsies that are used in our models
ISO9001 certification
Genoskin obtains ISO9001 certification The entire Genoskin team is proud to announce that we obtained the ISO9001:2015 certification in January 2017. This certificate validates the quality and consistency of our design and R&D services as well as the commercialization of human skin models, cells and tissues to pharmaceutical, chemical and cosmetic industries. Consistent quality for skin models and R&D programs The
Genoskin develops and markets innovative testing tools to study the effects of pharmaceutical, cosmetic and chemical products on real, live ex vivo human skin.